CD19-directed CAR T-cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-cell acute lymphoblastic leukemia. – Logos Biosystems | Advanced Imaging Solutions for Research Excellence

Products

< Back

Customer Reviews

< Back

Resources

< Back

Support

< Back

About Us

< Back

CD19-directed CAR T-cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-cell acute lymphoblastic leukemia.

2018-11-20

2018. Chong EA, Levine BL, Grupp SA, Davis M, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, June CH, Schuster SJ. Blood 132 (Suppl 1): 197.